Last reviewed · How we verify

Panic disorder — Treatment Landscape & Competitive Intelligence

Panic disorder (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Panic disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Effexor venlafaxine Generic (originally Wyeth/Pfizer) SNRI (Serotonin-norepinephrine reuptake inhibitor) 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C 1993-12-28
Effexor Venlafaxine Hydrochloride Pfizer Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Serotonin and norepinephrine reuptake transporters 1993-01-01
Zoloft sertraline Pfizer Inc. SSRI (Selective serotonin reuptake inhibitor) Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A 1991-12-30
Prozac fluoxetine Eli Lilly and Company Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin reuptake transporter 1987-12-29
Xanax alprazolam Generic (originally Upjohn/Pfizer) Benzodiazepine (triazolobenzodiazepine) Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4 1981-10-16
Ativan lorazepam Generic (originally Wyeth/Pfizer) Benzodiazepine [EPC] GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver 1977-09-30
Klonopin clonazepam Generic (originally Roche) Benzodiazepine [EPC] GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel 1975-06-04
Prozac Prozac RenJi Hospital Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A
Xanax Xanax National Taiwan University Hospital Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4
Klonopin Klonopin Par Pharmaceutical, Inc. GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Wyeth/Pfizer) · 2 drugs in Panic disorder
  2. Generic (originally Roche) · 1 drug in Panic disorder
  3. Generic (originally Upjohn/Pfizer) · 1 drug in Panic disorder
  4. National Taiwan University Hospital · 1 drug in Panic disorder
  5. Par Pharmaceutical, Inc. · 1 drug in Panic disorder
  6. Pfizer · 1 drug in Panic disorder
  7. Pfizer Inc. · 1 drug in Panic disorder
  8. Poznan University of Medical Sciences · 1 drug in Panic disorder
  9. RenJi Hospital · 1 drug in Panic disorder
  10. Eli Lilly and Company · 1 drug in Panic disorder
  11. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in Panic disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Panic disorder:

Cite this brief

Drug Landscape (2026). Panic disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/panic-disorder. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing